New Diabetes Treatment Protocol Cuts Hypoglycemia Risk by 50%

Spanish researchers have developed a treatment protocol called Endocare that reduces the risk of hypoglycemia by 50% in hospitalized patients with type 2 diabetes. The method combines insulin with specific oral medications to improve blood sugar control, according to reports from Infobae and Diario de Alicante.

The protocol focuses on patients admitted to hospitals, where managing glucose levels is often complicated by acute illness and varying medication needs. According to Isabial, the model serves as an alternative to insulin-only treatments for these specific patient populations.

How does the Endocare protocol reduce hypoglycemia?

Endocare integrates insulin therapy with other pharmacological agents to stabilize blood glucose. By combining these treatments, the protocol aims to prevent the sharp drops in blood sugar known as hypoglycemia, which can occur when insulin is used in isolation or improperly dosed in a hospital setting.

Diario de Alicante reports that the protocol has successfully cut the incidence of these hypoglycemic episodes in half. This reduction is critical because severe hypoglycemia in hospitalized patients can lead to cognitive impairment, prolonged hospital stays, and increased mortality.

Why is this treatment significant for type 2 diabetes?

Type 2 diabetes management often requires a transition between oral medications and insulin as the disease progresses or during acute medical crises. The Endocare model provides a structured way to bridge these treatments without triggering dangerous glucose fluctuations.

According to Consalud, the Isabial-endorsed model provides a safer alternative for patients who would otherwise rely solely on insulin while admitted. By maintaining a combination of drugs, the body’s glucose response is more balanced, reducing the volatility typically seen in insulin-only regimens.

What are the primary outcomes of the research?

The research highlights two primary outcomes for the Endocare protocol:

• Hypoglycemia Reduction: A 50% decrease in the risk of low blood sugar episodes among the studied patient group.
• Improved Glycemic Control: Better overall regulation of sugar levels when insulin is paired with other medications rather than used alone.

Infobae notes that this discovery offers a new pathway for treating type 2 diabetes by shifting the focus toward a synergistic approach between different classes of glucose-lowering drugs.

How does this compare to standard hospital care?

Standard care for hospitalized diabetic patients often involves “sliding scale” insulin, where doses are adjusted based on current glucose readings. However, this method can sometimes lead to “over-correction,” resulting in hypoglycemia.

The Endocare protocol differs by utilizing a combined pharmacological approach. While traditional methods may prioritize the rapid lowering of glucose via insulin, the Spanish researchers’ model emphasizes stability through the integration of oral drugs, which the reporting suggests leads to a more consistent glucose profile.